Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South Korea Swollen Knee Treatment Market

ID: MRFR/HC/55029-HCR
200 Pages
Satyendra Maurya
March 2026

South Korea Swollen Knee Treatment Market Research Report By Type (Medications, Surgery) and By End User (Hospitals, Clinics) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South Korea Swollen Knee Treatment Market Infographic
Purchase Options

South Korea Swollen Knee Treatment Market Summary

As per Market Research Future analysis, the South Korea swollen knee-treatment market size was estimated at 27.0 USD Million in 2024.. The South Korea swollen knee-treatment market is projected to grow from 28.75 USD Million in 2025 to 54.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The South Korea swollen knee-treatment market is experiencing a shift towards non-surgical solutions and technological integration.

  • The market shows a rising demand for non-surgical treatments, particularly in the largest segment of physical therapy.
  • Integration of technology in treatment methods is becoming increasingly prevalent, enhancing patient outcomes.
  • There is a growing focus on preventive care and education, especially in the fastest-growing segment of wellness programs.
  • Key market drivers include the increasing prevalence of knee disorders and advancements in medical technology, which are shaping treatment options.

Market Size & Forecast

2024 Market Size 27.0 (USD Million)
2035 Market Size 54.0 (USD Million)
CAGR (2025 - 2035) 6.5%

Major Players

Johnson & Johnson (US), Bayer AG (DE), Pfizer Inc. (US), Novartis AG (CH), AbbVie Inc. (US), GlaxoSmithKline plc (GB), Sanofi S.A. (FR), Merck & Co., Inc. (US), Amgen Inc. (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

South Korea Swollen Knee Treatment Market Trends

The swollen knee-treatment market in South Korea is currently experiencing notable developments. This growth is driven by an increasing awareness of joint health and the rising prevalence of knee-related ailments.. The population's aging demographic appears to be a significant factor, as older individuals often face conditions such as osteoarthritis, which can lead to swelling and discomfort in the knee area. Furthermore, advancements in medical technology and treatment options, including minimally invasive procedures and innovative pharmaceuticals, seem to enhance patient outcomes and satisfaction. This evolving landscape suggests a growing demand for effective treatment solutions, which may lead to increased investment in research and development within the sector. In addition, the healthcare system in South Korea is characterized by its accessibility and high standards, which likely contribute to the rising number of patients seeking treatment for swollen knees. The integration of traditional medicine with modern practices may also play a role in shaping treatment approaches. As healthcare providers continue to adapt to patient needs, the swollen knee-treatment market is expected to continue growing.. The emphasis on preventive care and rehabilitation strategies indicates a shift towards holistic management of knee health, which could redefine treatment paradigms in the near future.

Rising Demand for Non-Surgical Treatments

There is an increasing preference for non-invasive treatment options in the swollen knee-treatment market. Patients are showing a tendency to opt for therapies such as physical rehabilitation, corticosteroid injections, and hyaluronic acid injections, which may provide relief without the need for surgery. This trend reflects a broader shift towards conservative management of knee conditions.

Integration of Technology in Treatment

The incorporation of advanced technologies, such as telemedicine and mobile health applications, is transforming the swollen knee-treatment market. These innovations facilitate remote consultations and monitoring, allowing healthcare providers to offer personalized care. This trend may enhance patient engagement and adherence to treatment plans.

Focus on Preventive Care and Education

There is a growing emphasis on preventive measures and patient education within the swollen knee-treatment market. Healthcare professionals are increasingly advocating for lifestyle modifications, such as weight management and exercise, to prevent knee issues. This proactive approach may lead to better long-term outcomes for patients.

South Korea Swollen Knee Treatment Market Drivers

Rising Healthcare Expenditure

In South Korea, increasing healthcare expenditure is a crucial driver for the swollen knee-treatment market. The government has been investing heavily in healthcare infrastructure and services, with spending projected to reach 10% of GDP by 2026. This financial commitment enhances access to various treatment options for knee disorders, including both surgical and non-surgical interventions. As patients become more aware of available treatments, the demand for effective solutions is likely to rise. Moreover, the expansion of health insurance coverage for knee treatments encourages more individuals to seek care, further propelling market growth. The combination of higher spending and improved access to treatments positions the swollen knee-treatment market for significant expansion in the coming years.

Growing Awareness of Joint Health

There is a noticeable increase in public awareness regarding joint health in South Korea, which is positively influencing the swollen knee-treatment market. Educational campaigns and health initiatives aimed at promoting joint care are becoming more prevalent. As individuals become more informed about the importance of maintaining joint health, they are more likely to seek treatment for knee swelling and related issues. This trend is supported by surveys indicating that over 60% of the population recognizes the impact of lifestyle choices on joint health. Consequently, healthcare providers are responding by offering more targeted treatment options, which may lead to a surge in demand for services within the swollen knee-treatment market. This heightened awareness is expected to drive market growth as more individuals prioritize their joint health.

Advancements in Medical Technology

Technological innovations in medical devices and treatment methodologies are transforming the swollen knee-treatment market. The introduction of minimally invasive surgical techniques and advanced imaging technologies enhances diagnostic accuracy and treatment efficacy. For instance, the use of arthroscopy has gained traction, allowing for quicker recovery times and reduced hospital stays. Additionally, the integration of telemedicine facilitates remote consultations, making it easier for patients to access care. In South Korea, the medical technology sector is projected to grow at a CAGR of 8% over the next five years, indicating a robust environment for the development of new treatment options. These advancements not only improve patient outcomes but also stimulate market growth by attracting more patients seeking innovative solutions.

Increasing Prevalence of Knee Disorders

The rising incidence of knee disorders in South Korea appears to be a significant driver for the swollen knee-treatment market. Factors such as an aging population and sedentary lifestyles contribute to this trend. According to recent health statistics, approximately 30% of adults over 60 experience knee-related issues, which may lead to swelling. This growing demographic is likely to seek effective treatment options, thereby expanding the market. Furthermore, the prevalence of obesity, which affects around 35% of the adult population, exacerbates knee problems, leading to increased demand for various treatment modalities. As healthcare providers focus on addressing these conditions, the swollen knee-treatment market is expected to experience substantial growth in response to the rising need for effective interventions.

Increase in Sports and Physical Activities

The growing participation in sports and physical activities among South Koreans is emerging as a significant driver for the swollen knee-treatment market. As more individuals engage in high-impact sports, the incidence of knee injuries and subsequent swelling is likely to rise. Recent studies indicate that approximately 20% of athletes experience knee-related issues, which can lead to swelling and require treatment. This trend is further supported by the increasing popularity of fitness and recreational activities, particularly among younger demographics. As awareness of the importance of injury prevention and management grows, there is a corresponding increase in demand for effective treatment options. Consequently, the swollen knee-treatment market is poised to benefit from this surge in activity levels, as more individuals seek solutions for knee-related concerns.

Market Segment Insights

By Type: Medications (Largest) vs. Surgery (Fastest-Growing)

In the South Korea swollen knee-treatment market, the medications segment holds the largest share as it encompasses various therapies aimed at reducing pain and inflammation. This includes both over-the-counter and prescription drugs that target symptoms associated with swollen knees, making it a preferred choice among both patients and healthcare providers. On the other hand, surgery, while currently having a smaller market share, is rapidly gaining traction due to advances in surgical techniques and increased patient understanding of orthopedic correction options. The growth trends in this segment are significantly influenced by the rising prevalence of knee-related conditions among the aging population in South Korea. Innovations in minimally invasive surgical procedures have made surgeries more appealing, driving demand. Additionally, the ongoing development of new medications tailored for pain relief and anti-inflammatory effects is fostering a competitive environment. The dual role of medications as both first-line treatments and pre-operative care enhances their market position while surgery's increased adoption signals a shift toward comprehensive treatment approaches.

Medications (Dominant) vs. Surgery (Emerging)

Medications represent the dominant force within the South Korea swollen knee-treatment market, as they are widely accessible and provide immediate relief for patients experiencing discomfort. This category includes a variety of non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids that are utilized for their effective pain-relieving properties. By offering a non-invasive option, medications serve as the first line of treatment, allowing patients to manage symptoms before considering more invasive procedures. In contrast, surgery is emerging as a vital component of treatment options, especially for patients not responding to conservative therapies. As surgical methods continue to evolve, particularly in areas like arthroscopy and joint replacements, an increasing number of healthcare professionals advocate for surgical intervention as a long-term solution, thereby changing the dynamics of patient management in the market.

By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

The South Korea swollen knee-treatment market exhibits a diverse distribution across its end-user segments, with hospitals commanding the largest market share. The extensive resources and specialized services provided by hospitals position them as the mainstay for swollen knee treatments. Meanwhile, clinics are rapidly gaining traction, reflecting a growing preference among patients for accessible and efficient treatment options. This shift underscores the evolving dynamics within the healthcare sector, where patients are increasingly seeking outpatient services. Significant growth trends are evident in the clinics segment, driven by factors such as rising patient awareness and the emphasis on minimally invasive procedures. Ambulatory surgery centers are also emerging as viable alternatives, offering convenience and cost-effectiveness. As patient preferences evolve, the South Korea swollen knee-treatment market is likely to witness further shifts, with clinics potentially becoming a more prominent player in the years to come.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals in the South Korea swollen knee-treatment market are characterized by their comprehensive care capabilities, equipped with advanced technologies and specialists needed for complex cases. They maintain a dominant position due to their ability to provide extensive inpatient and outpatient services, making them the preferred choice for serious conditions. Conversely, clinics are emerging as significant contenders, focusing on providing rapid access and personalized care. These facilities often cater to routine cases with shorter recovery times, appealing to a broader patient demographic. As healthcare evolves, the ability of clinics to offer specialized services and meet patient expectations will determine their growth trajectory within the market.

Get more detailed insights about South Korea Swollen Knee Treatment Market

Key Players and Competitive Insights

The swollen knee-treatment market in South Korea is characterized by a competitive landscape that is both dynamic and multifaceted. Key growth drivers include an aging population, increasing prevalence of knee-related ailments, and advancements in treatment methodologies. Major players such as Johnson & Johnson (US), Pfizer Inc. (US), and AbbVie Inc. (US) are strategically positioned to leverage innovation and regional expansion. Their operational focus on developing advanced therapeutic solutions and enhancing patient outcomes appears to be shaping the competitive environment, fostering a climate of continuous improvement and adaptation.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure is moderately fragmented, with several key players exerting considerable influence. This fragmentation allows for a diverse range of treatment options, yet the collective strategies of these companies suggest a trend towards consolidation and collaboration, particularly in research and development initiatives.

In October Johnson & Johnson (US) announced a partnership with a local South Korean biotech firm to co-develop a novel knee treatment that utilizes regenerative medicine techniques. This strategic move is significant as it not only enhances Johnson & Johnson's product portfolio but also aligns with the growing trend towards personalized medicine, potentially improving patient outcomes and satisfaction.

In September Pfizer Inc. (US) launched a new digital health platform aimed at providing real-time monitoring and support for patients undergoing knee treatments. This initiative reflects a broader industry trend towards digitalization, suggesting that Pfizer is keen on integrating technology into patient care, which may enhance adherence to treatment protocols and improve overall health outcomes.

In August AbbVie Inc. (US) expanded its clinical trial program for a new biologic therapy targeting knee osteoarthritis, with a focus on the South Korean market. This expansion indicates AbbVie's commitment to addressing unmet medical needs in the region and highlights the importance of clinical research in driving innovation within the swollen knee-treatment market.

As of November current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing the reliability of supply chains. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative treatment solutions, and robust supply chain management, thereby ensuring that companies remain agile and responsive to the changing needs of the market.

Key Companies in the South Korea Swollen Knee Treatment Market include

Industry Developments

Recent developments in the South Korea Swollen Knee Treatment Market indicate a focus on innovation and strategic collaborations among major players. In October 2023, Merck & Co. announced an expansion of its product offering, enhancing treatment options for patients with knee-related issues. Meanwhile, Stryker introduced advanced minimally invasive surgical techniques aimed at improving patient outcomes in knee surgery. In terms of mergers and acquisitions, Abbott Laboratories completed the acquisition of a local biomedical firm in September 2023, which aims to enhance its treatment portfolio targeted at joint problems. 

The market has also seen significant growth, with estimates indicating an increase in valuation due to rising healthcare spending and advancements in therapeutics and medical devices. Companies like Samsung Biologics have reported increased investments in Research and Development to innovate and deliver effective treatment solutions. Over the past few years, key milestones include Baxter’s collaboration with local hospitals for clinical trials in knee treatment advancements in July 2022. This evolving landscape reflects the ongoing commitment to improve healthcare outcomes in South Korea, driven by both local and multinational companies.

Future Outlook

South Korea Swollen Knee Treatment Market Future Outlook

The Swollen Knee Treatment Market is projected to grow at a 6.5% CAGR from 2025 to 2035, driven by increasing prevalence of knee disorders and advancements in treatment technologies.

New opportunities lie in:

  • Development of telehealth platforms for remote consultations and follow-ups.
  • Investment in regenerative medicine techniques for knee treatment.
  • Expansion of personalized treatment plans using AI-driven analytics.

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment methodologies and patient needs.

Market Segmentation

South Korea Swollen Knee Treatment Market Type Outlook

  • Medications
  • Patient-controlled analgesia (PCA) pumps
  • Nerve blocks
  • Liposomal bupivacaine
  • Surgery

South Korea Swollen Knee Treatment Market End-User Outlook

  • Hospitals
  • Clinics
  • Ambulatory Surgery Centers
  • Others

Report Scope

MARKET SIZE 2024 27.0(USD Million)
MARKET SIZE 2025 28.75(USD Million)
MARKET SIZE 2035 54.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.5% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Johnson & Johnson (US), Bayer AG (DE), Pfizer Inc. (US), Novartis AG (CH), AbbVie Inc. (US), GlaxoSmithKline plc (GB), Sanofi S.A. (FR), Merck & Co., Inc. (US), Amgen Inc. (US)
Segments Covered Type, End-User
Key Market Opportunities Emergence of innovative therapies addressing chronic inflammation in the swollen knee-treatment market.
Key Market Dynamics Rising demand for innovative therapies drives competition in the swollen knee-treatment market in South Korea.
Countries Covered South Korea
Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Garvit Vyas LinkedIn
Vice President - Operations
Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.
Leave a Comment

FAQs

What was the market valuation for the swollen knee-treatment market in 2024?

<p>The market valuation for the swollen knee-treatment market was $27.0 Million in 2024.</p>

What is the projected market valuation for 2035?

<p>The projected market valuation for 2035 is $54.0 Million.</p>

What is the expected CAGR for the swollen knee-treatment market during the forecast period 2025 - 2035?

<p>The expected CAGR for the swollen knee-treatment market during the forecast period 2025 - 2035 is 6.5%.</p>

Which companies are considered key players in the swollen knee-treatment market?

<p>Key players in the swollen knee-treatment market include Johnson & Johnson, Bayer AG, Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline plc, Sanofi S.A., Merck & Co., Inc., and Amgen Inc.</p>

What are the main segments of the swollen knee-treatment market?

<p>The main segments of the swollen knee-treatment market include medications, patient-controlled analgesia (PCA) pumps, nerve blocks, liposomal bupivacaine, and surgery.</p>

How much revenue did medications generate in the swollen knee-treatment market?

<p>Medications generated revenue ranging from $10.0 Million to $20.0 Million in the swollen knee-treatment market.</p>

What is the revenue range for patient-controlled analgesia (PCA) pumps?

<p>The revenue range for patient-controlled analgesia (PCA) pumps is between $5.0 Million and $10.0 Million.</p>

What is the revenue contribution of hospitals as an end-user in the market?

<p>Hospitals contributed revenue ranging from $10.8 Million to $21.6 Million as an end-user in the swollen knee-treatment market.</p>

What revenue did clinics generate in the swollen knee-treatment market?

<p>Clinics generated revenue between $7.2 Million and $14.4 Million in the swollen knee-treatment market.</p>

What is the revenue range for ambulatory surgery centers in the market?

<p>Ambulatory surgery centers generated revenue ranging from $5.4 Million to $10.8 Million in the swollen knee-treatment market.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions